Mercury Therapeutics, Inc. (âMTIâ) had been a biopharmaceutical company focused on developing breakthrough treatments for cancer and metabolic disease. MTIâs expertise lay in developing small molecule drugs against targets in the signal transduction pathways that control tumor growth and energy metabolism. The Company had proprietary lead generation programs that target the Ras-MAP Kinase pathway in cancer and AMP activated protein kinase for diabetes and the Metabolic Syndrome. In late 2002, Mercury acquired exclusive, worldwide rights to an oncology-drug technology from Massachusetts General Hospital. The firm is focused on using the technology to develop small-molecule inhibitors to the Ras-Raf protein interaction. The firm also had a multi-year collaboration with Aventis and an exclusive license agreement with Debiopharm Group for the development and commercialisation of Debio 0930, a small molecule activator of AMPK (adenosine monophosphate activated protein kinase) for the treatment of diabetes and metabolic diseases. With the intimely death of the founder of the firm, Mercury Therapeutics ceased operation in